Xpert Carba-R
FDA 510(k) K261867 · Cepheid®
510(k) numberK261867
Submission
- Device name
- Xpert Carba-R
- Applicant
- Cepheid®
Sunnyvale, CA, US - Received
- June 4, 2026
- Decision date
- July 2, 2026
- Decision
- Substantially Equivalent (SESE)
- Type
- Special 510(k)
- Summary
- 510(k) summary available from FDA
Device classification
- Product code
- POC – System, Nucleic Acid Amplification Test, Dna, Antimicrobial Resistance Marker, Direct Specimen
- Device class
- Class II (moderate risk)
- Regulation
- 21 CFR 866.1640
- Specialty
- Microbiology
To detect the presence of genetic markers of antimicrobial resistance by testing directly from clinical specimens using nucleic acid amplification technology.
Other 510(k)s with product code POC
More from Cepheid
| 510(k) | Device | Decision |
|---|---|---|
| K261362 | Xpert Hemorrhagic FeverQVR · Dual Track | 08/07/2026SE |
| K253653 | Xpert Hemorrhagic Fever · Traditional | 02/20/2026SE |
| K251721 | Xpert GI PanelPCH · Traditional | 01/16/2026SE |
| K250996 | Xpert Xpress CoV-2/Flu/RSV plusQOF · Special | 05/01/2025SE |
| K250995 | Xpert Xpress CoV-2/Flu/RSV plusQOF · Special | 05/01/2025SE |
| K243730 | Xpert C. difficile/EpiOZN · Traditional | 02/28/2025SE |
| K250218 | Xpert® FII & FVNPR · Special | 02/21/2025SE |
| K242109 | Xpert® Xpress CoV-2 plus (XPRS-COV2-10)QQX · Dual Track | 01/15/2025SE |
| K242071 | Xpert Xpress CoV-2/Flu/RSV plusQOF · Dual Track | 01/10/2025SE |
| K243625 | Xpert MRSA/SA SSTINQX · Special | 12/18/2024SE |
Questions and answers
When was Xpert Carba-R cleared by the FDA?
Xpert Carba-R (K261867) received a 510(k) decision of Substantially Equivalent on July 2, 2026, 28 days after the submission was received.
What is the product code of K261867?
The FDA product code is POC – System, Nucleic Acid Amplification Test, Dna, Antimicrobial Resistance Marker, Direct Specimen, a Class II (moderate risk) device regulated under 21 CFR 866.1640.